Evidence map›Paper›PMID 38097580›Full record

ArticleNature communications2023

Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.

Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C Garrido-Castro, Romualdo Barroso-Sousa and 17 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Paolo Tarantino *Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-8686-0228
Hersh Gupta *Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Melissa E HughesMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Janet FilesMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah StraussMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gregory KirknerMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anne-Marie FeeneyMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yvonne LiMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ana C Garrido-CastroMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5989-6636
Romualdo Barroso-SousaDasa Institute for Education and Research (IEPD), Brasilia, Brazil.
Brittany L BychkovskyBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7969-0603
Simona DiLascioMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lynette ShollMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9532-9735
Laura MacConaillMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Neal LindemanMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bruce E JohnsonMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew MeyersonMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9133-8108
Rinath JeselsohnMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7996-7529
Xintao QiuMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8560-7017
Rong LiMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0000-1046-9580
Henry LongMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6849-6629
Eric P WinerYale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA.
Deborah DillonHarvard Medical School, Boston, MA, USA.
Giuseppe CuriglianoDivision of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy.ORCID http://orcid.org/0000-0003-1781-2518
Andrew D CherniackMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sara M TolaneyMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671
Nancy U LinMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38097580
PMCPMC10721787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.